Fycompa(perampanel)
Fycompa (perampanel) is a small molecule pharmaceutical. Perampanel was first approved as Fycompa on 2012-07-23. It is used to treat partial epilepsies, seizures, and tonic-clonic epilepsy in the USA. It has been approved in Europe to treat partial epilepsies.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Fycompa
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fycompa | New Drug Application | 2021-02-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| partial epilepsies | EFO_0004263 | D004828 | — |
| seizures | HP_0007359 | D012640 | G40.4 |
| tonic-clonic epilepsy | EFO_0007262 | D004830 | — |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
96 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 7 | 3 | 7 | 9 | 26 |
| Seizures | D012640 | G40.4 | 1 | 4 | 4 | 1 | 5 | 14 | |
| Healthy volunteers/patients | — | 8 | — | — | 1 | — | 9 | ||
| Partial epilepsies | D004828 | EFO_0004263 | — | — | — | 1 | 2 | 3 | |
| Glioma | D005910 | EFO_0000520 | 1 | 1 | — | 1 | — | 2 | |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | — | 1 | 1 | — | 2 |
| Drug resistant epilepsy | D000069279 | — | — | — | 1 | — | 1 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | 1 | — | 1 |
| Electroencephalography | D004569 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 6 | 5 | — | — | 11 |
| Lennox gastaut syndrome | D065768 | G40.81 | — | — | 1 | — | 1 | 2 | |
| Neuralgia | D009437 | EFO_0009430 | — | 2 | 1 | — | — | 2 | |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 1 | — | — | 1 | 3 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 2 | 2 | — | — | — | 2 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 1 | — | — | — | 1 |
| Small fiber neuropathy | D000071075 | — | 1 | — | — | — | 1 | ||
| Torticollis | D014103 | HP_0000473 | F45.8 | 1 | 1 | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | — | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PERAMPANEL |
| INN | perampanel |
| Description | Perampanel is a member of the class of bipyridines that is 2,3'-bipyridin-6'-one substituted at positions 1' and 5' by phenyl and 2-cyanophenyl groups respectively. Used as an adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy. It has a role as an AMPA receptor antagonist and an anticonvulsant. It is a pyridone, a nitrile and a member of bipyridines. It is functionally related to a benzonitrile. |
| Classification | Small molecule |
| Drug class | ionotropic non-NMDA (N-methyl D-aspartate) glutamate receptors [AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and/or KA (kainite antagonist) receptors]: antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O |
Identifiers
| PDB | — |
| CAS-ID | 380917-97-5 |
| RxCUI | 1356552 |
| ChEMBL ID | CHEMBL1214124 |
| ChEBI ID | 71013 |
| PubChem CID | 9924495 |
| DrugBank | DB08883 |
| UNII ID | H821664NPK (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Fycompa - CATALYST PHARMACEUTICALS, INC.
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,897 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fycompa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,810 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more